Lipum AB (OSTO:LIPUM) EBIT per Share : kr-1.87 (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Lipum AB EBIT per Share?

Lipum AB's EBIT per Share for the three months ended in Dec. 2023 was kr-0.97. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was kr-1.87.

During the past 3 years, the average EBIT per Share Growth Rate was -3.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Lipum AB's EBIT per Share or its related term are showing as below:

OSTO:LIPUM' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -53.2 Med: -28.35 Max: -3.5
Current: -3.5

During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Lipum AB was -3.50% per year. The lowest was -53.20% per year. And the median was -28.35% per year.

OSTO:LIPUM's 3-Year EBIT Growth Rate is ranked worse than
58.5% of 1311 companies
in the Biotechnology industry
Industry Median: 3.7 vs OSTO:LIPUM: -3.50

Lipum AB's EBIT for the three months ended in Dec. 2023 was kr-9.41 Mil.

Lipum AB EBIT per Share Historical Data

The historical data trend for Lipum AB's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipum AB EBIT per Share Chart

Lipum AB Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

-1.78

-4.01

-12.08

-6.42

-4.27

Lipum AB Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial										-1.88	-1.63	-0.90	-	-0.97

Lipum AB EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Lipum AB's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-37.047	/	8.669
=	-4.27

Lipum AB's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-9.414	/	9.675
=	-0.97

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-1.87

Lipum AB (OSTO:LIPUM) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Lipum AB EBIT per Share Related Terms

Thank you for viewing the detailed overview of Lipum AB's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Lipum AB (OSTO:LIPUM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipum AB (OSTO:LIPUM) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

Tvistevagen 48 C, Umea, SWE, 907 36

Website

https://www.lipum.se

Lipum AB is a clinical-stage biopharmaceutical company specializing in the discovery and development of a novel treatment for chronic inflammatory diseases. The candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule (BSSL) of the immune system. The development is supported by solid pre-clinical data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need.

Lipum AB (OSTO:LIPUM) Headlines

No Headlines